{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:01Z","timestamp":1790673901674,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R21DK103118"],"award-info":[{"award-number":["R21DK103118"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 HG007963"],"award-info":[{"award-number":["U54 HG007963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lifetime Data Anal"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10985-019-09473-1","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T08:03:57Z","timestamp":1555056237000},"page":"245-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Assessing the value of a censored surrogate outcome"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7288-1009","authenticated-orcid":false,"given":"Layla","family":"Parast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"5","key":"9473_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KGMM Alberti","year":"2006","unstructured":"Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome? A new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469\u2013480","journal-title":"Diabet Med"},{"key":"9473_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT","year":"2000","unstructured":"ALLHAT (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). Jama 283:1967\u20131975","journal-title":"Jama"},{"key":"9473_CR3","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/jnci\/djp369","volume":"101","author":"KR Broglio","year":"2009","unstructured":"Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642\u20131649","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"9473_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/1467-9876.00244","volume":"50","author":"T Burzykowski","year":"2001","unstructured":"Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D (2001) Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C (Appl Stat) 50(4):405\u2013422","journal-title":"J R Stat Soc Ser C (Appl Stat)"},{"issue":"3","key":"9473_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2307\/2533853","volume":"54","author":"M Buyse","year":"1998","unstructured":"Buyse M, Molenberghs G (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54(3):1014\u20131029","journal-title":"Biometrics"},{"issue":"33","key":"9473_CR6","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25(33):5218\u20135224","journal-title":"J Clin Oncol"},{"issue":"9102","key":"9473_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","volume":"351","author":"DW Cameron","year":"1998","unstructured":"Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A et al (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Lancet 351(9102):543\u2013549","journal-title":"The Lancet"},{"issue":"9","key":"9473_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7326\/0003-4819-118-9-199305010-00003","volume":"118","author":"S Choi","year":"1993","unstructured":"Choi S, Lagakos SW, Schooley RT, Volberding PA (1993) Cd4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 118(9):674\u2013680","journal-title":"Ann Intern Med"},{"issue":"2","key":"9473_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/biostatistics\/kxt051","volume":"15","author":"AS Conlon","year":"2014","unstructured":"Conlon AS, Taylor JM, Elliott MR (2014) Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal. Biostatistics 15(2):266\u2013283","journal-title":"Biostatistics"},{"issue":"5","key":"9473_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/00005082-200509000-00008","volume":"20","author":"JA Eastwood","year":"2005","unstructured":"Eastwood JA, Doering LV (2005) Gender differences in coronary artery disease. J Cardiovasc Nurs 20(5):340\u2013351","journal-title":"J Cardiovasc Nurs"},{"issue":"7117","key":"9473_CR11","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.315.7117.1194","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M (1997) Impact of new antiretroviral combination therapies in HIV infected patients in switzerland: prospective multicentre study. Bmj 315(7117):1194\u20131199","journal-title":"Bmj"},{"issue":"2","key":"9473_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/biostatistics\/kxu043","volume":"16","author":"MR Elliott","year":"2015","unstructured":"Elliott MR, Conlon AS, Li Y, Kaciroti N, Taylor JM (2015) Surrogacy marker paradox measures in meta-analytic settings. Biostatistics 16(2):400\u2013412","journal-title":"Biostatistics"},{"key":"9473_CR13","unstructured":"FDA (2008) Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. \nhttps:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm071624.pdf\n\n. Accessed 9 Apr 2019"},{"issue":"9","key":"9473_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/sim.4780130906","volume":"13","author":"TR Fleming","year":"1994","unstructured":"Fleming TR, Prentice RL, Pepe MS, Glidden D (1994) Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and aids research. Stat Med 13(9):955\u2013968","journal-title":"Stat Med"},{"issue":"1","key":"9473_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.0006-341X.2002.00021.x","volume":"58","author":"CE Frangakis","year":"2002","unstructured":"Frangakis CE, Rubin DB (2002) Principal stratification in causal inference. Biometrics 58(1):21\u201329","journal-title":"Biometrics"},{"issue":"2","key":"9473_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/sim.4780110204","volume":"11","author":"LS Freedman","year":"1992","unstructured":"Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11(2):167\u2013178","journal-title":"Stat Med"},{"issue":"2","key":"9473_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabres.2013.09.007","volume":"102","author":"S Frontoni","year":"2013","unstructured":"Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A (2013) Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract 102(2):86\u201395","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"9473_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/sim.6349","volume":"34","author":"EE Gabriel","year":"2015","unstructured":"Gabriel EE, Sachs MC, Gilbert PB (2015) Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints. Stat Med 34(3):381\u2013395","journal-title":"Stat Med"},{"issue":"1","key":"9473_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1541-0420.2007.00834.x","volume":"64","author":"D Ghosh","year":"2008","unstructured":"Ghosh D (2008) Semiparametric inference for surrogate endpoints with bivariate censored data. Biometrics 64(1):149\u2013156","journal-title":"Biometrics"},{"issue":"2","key":"9473_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1541-0420.2008.01109.x","volume":"65","author":"D Ghosh","year":"2009","unstructured":"Ghosh D (2009) On assessing surrogacy in a single trial setting using a semicompeting risks paradigm. Biometrics 65(2):521\u2013529","journal-title":"Biometrics"},{"issue":"4","key":"9473_CR21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/j.1541-0420.2008.01014.x","volume":"64","author":"PB Gilbert","year":"2008","unstructured":"Gilbert PB, Hudgens MG (2008) Evaluating candidate principal surrogate endpoints. Biometrics 64(4):1146\u20131154","journal-title":"Biometrics"},{"issue":"15","key":"9473_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJM199610103351501","volume":"335","author":"S Hammer","year":"1996","unstructured":"Hammer S, Katzenstein D, Hughes M, Gundacker H, Schooley R, Haubrich R, Henry W, Lederman M, Phair J, Niu M et al (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 335(15):1081\u20131090","journal-title":"N Engl J Med"},{"issue":"4","key":"9473_CR23","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1541-0420.2011.01603.x","volume":"67","author":"Y Huang","year":"2011","unstructured":"Huang Y, Gilbert PB (2011) Comparing biomarkers as principal surrogate endpoints. Biometrics 67(4):1442\u20131451","journal-title":"Biometrics"},{"issue":"14","key":"9473_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/00002030-199814000-00014","volume":"12","author":"MD Hughes","year":"1998","unstructured":"Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT (1998) Cd4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the aids clinical trials group. Aids 12(14):1823\u20131832","journal-title":"Aids"},{"issue":"1","key":"9473_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.ajkd.2014.02.020","volume":"64","author":"LA Inker","year":"2014","unstructured":"Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T, Collaboration CKDE et al (2014) Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64(1):74\u201385","journal-title":"Am J Kidney Dis"},{"issue":"7340","key":"9473_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/bmj.324.7340.757","volume":"324","author":"R Jordan","year":"2002","unstructured":"Jordan R, Gold L, Cummins C, Hyde C (2002) Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. Bmj 324(7340):757","journal-title":"Bmj"},{"issue":"9156","key":"9473_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","volume":"353","author":"B Ledergerber","year":"1999","unstructured":"Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H et al (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. The Lancet 353(9156):863\u2013868","journal-title":"The Lancet"},{"issue":"9","key":"9473_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/sim.4780120904","volume":"12","author":"D Lin","year":"1993","unstructured":"Lin D, Fischl MA, Schoenfeld D (1993) Evaluating the role of cd4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 12(9):835\u2013842","journal-title":"Stat Med"},{"issue":"13","key":"9473_CR29","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1","volume":"16","author":"D Lin","year":"1997","unstructured":"Lin D, Fleming T, De Gruttola V et al (1997) Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16(13):1515\u20131527","journal-title":"Stat Med"},{"issue":"11","key":"9473_CR30","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.2337\/diacare.26.11.3153","volume":"26","author":"C Lorenzo","year":"2003","unstructured":"Lorenzo C, Williams K, Stern MP, Haffner SM (2003) The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care 26(11):3153\u20133159","journal-title":"Diabetes Care"},{"issue":"12","key":"9473_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","volume":"18","author":"A Maas","year":"2010","unstructured":"Maas A, Appelman Y (2010) Gender differences in coronary heart disease. Neth Heart J 18(12):598\u2013603","journal-title":"Neth Heart J"},{"key":"9473_CR32","unstructured":"NHLBI (2008) NHLBI data repository: prevention of events with angiotensin-converting enzyme inhibitor therapy (peace). \nhttps:\/\/biolincc.nhlbi.nih.gov\/studies\/peace\/\n\n. Accessed 9 Apr 2019"},{"issue":"20","key":"9473_CR33","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1002\/sim.5776","volume":"32","author":"L Parast","year":"2013","unstructured":"Parast L, Cai T (2013) Landmark risk prediction of residual life for breast cancer survival. Stat Med 32(20):3459\u20133471. \nhttps:\/\/doi.org\/10.1002\/sim.5776","journal-title":"Stat Med"},{"issue":"10","key":"9473_CR34","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/sim.6820","volume":"35","author":"L Parast","year":"2016","unstructured":"Parast L, McDermott MM, Tian L (2016) Robust estimation of the proportion of treatment effect explained by surrogate marker information. Stat Med 35(10):1637\u20131653","journal-title":"Stat Med"},{"issue":"11","key":"9473_CR35","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/sim.7220","volume":"36","author":"L Parast","year":"2017","unstructured":"Parast L, Cai T, Tian L (2017) Evaluating surrogate marker information using censored data. Stat Med 36(11):1767\u20131782","journal-title":"Stat Med"},{"issue":"351","key":"9473_CR36","first-page":"2058","volume":"2004","author":"PEACE","year":"2004","unstructured":"PEACE (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004(351):2058\u20132068","journal-title":"N Engl J Med"},{"issue":"13","key":"9473_CR37","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352(13):1293\u20131304","journal-title":"N Engl J Med"},{"issue":"2","key":"9473_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00001648-199203000-00013","volume":"3","author":"JM Robins","year":"1992","unstructured":"Robins JM, Greenland S (1992) Identifiability and exchangeability for direct and indirect effects. Epidemiology 3(2):143\u2013155","journal-title":"Epidemiology"},{"issue":"19","key":"9473_CR39","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","volume":"30","author":"P Royston","year":"2011","unstructured":"Royston P, Parmar MK (2011) The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 30(19):2409\u20132421","journal-title":"Stat Med"},{"issue":"1","key":"9473_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK (2013) Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 13(1):152","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"9473_CR41","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.00600206","volume":"1","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Greene T, Levey AS (2006) Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1(4):874\u2013884","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"9473_CR42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/biostatistics\/kxt050","volume":"15","author":"L Tian","year":"2013","unstructured":"Tian L, Zhao L, Wei L (2013) Predicting the restricted mean event time with the subject\u2019s baseline covariates in survival analysis. Biostatistics 15(2):222\u2013233","journal-title":"Biostatistics"},{"issue":"3","key":"9473_CR43","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/biom.12071","volume":"69","author":"TJ Van der Weele","year":"2013","unstructured":"Van der Weele TJ (2013) Surrogate measures and consistent surrogates. Biometrics 69(3):561\u2013565","journal-title":"Biometrics"},{"issue":"9440","key":"9473_CR44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. The Lancet 364(9440):1127\u20131134","journal-title":"The Lancet"},{"issue":"4","key":"9473_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.0006-341X.2002.00803.x","volume":"58","author":"Y Wang","year":"2002","unstructured":"Wang Y, Taylor JM (2002) A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 58(4):803\u2013812","journal-title":"Biometrics"},{"issue":"4","key":"9473_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/sim.4780080405","volume":"8","author":"J Wittes","year":"1989","unstructured":"Wittes J, Lakatos E, Probstfield J (1989) Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8(4):415\u2013425","journal-title":"Stat Med"}],"container-title":["Lifetime Data Analysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10985-019-09473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10985-019-09473-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10985-019-09473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:43:11Z","timestamp":1589722991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10985-019-09473-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["9473"],"URL":"https:\/\/doi.org\/10.1007\/s10985-019-09473-1","relation":{},"ISSN":["1380-7870","1572-9249"],"issn-type":[{"value":"1380-7870","type":"print"},{"value":"1572-9249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"28 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}